AGP Executive Report
Last update: 11 hours agoCancer Care Update: A Dana-Farber/Harvard-led ARACOG phase 2 analysis reports greater cognitive score decline with enzalutamide than darolutamide in prostate cancer, adding a new survivorship consideration for clinicians. Menopause & Sleep: Two studies spotlight women’s health—elinzanetant (NIRVANA) showed objective sleep improvements in postmenopausal vasomotor symptoms, and surgical menopause was linked to worse sexual and urinary symptoms than natural menopause. Nursing-Led Oncology Education: A nursing-centered briefing focuses on DLL3-directed therapies in small cell lung cancer, emphasizing toxicity monitoring and patient education. Narcolepsy Treatment Progress: Alkermes presented detailed positive Vibrance-2 phase 2 results for alixorexton in narcolepsy type 2, improving wakefulness and sleepiness. Public Health & Safety: Boston’s opioid overdose deaths fell to the lowest in a decade, with expanded naloxone access and training credited. Health Data Privacy: A report warns that the AI “gold rush” can put protected health information at risk, citing a major breach tied to an AI telehealth weight-loss provider. Massachusetts Community Health: The state’s beach water-quality dashboard is being updated hourly during beach season, with multiple sites listed as conditions change.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.